CD19 and mantle cell lymphoma: Another promising product investigated in MCL is LV20.19 CAR, a bispecific, tandem, lentiviral CAR-T cell targeting both CD20 and CD19 B-cell antigens, with 4-1BB co-stimulatory signaling.